Brown, Lisle/Cummings, Inc. Editas Medicine, Inc. Call Options Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EDIT
# of Institutions
243Shares Held
58.9MCall Options Held
494KPut Options Held
417K-
Vanguard Group Inc Valley Forge, PA8.03MShares$23.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.78MShares$22.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$17.4 Million0.92% of portfolio
-
State Street Corp Boston, MA4.59MShares$13.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.46MShares$7.13 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $199M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...